[HTML][HTML] Improving outcomes of tyrosine kinase inhibitors in hepatocellular carcinoma: new data and ongoing trials
L Mou, X Tian, B Zhou, Y Zhan, J Chen, Y Lu… - Frontiers in …, 2021 - frontiersin.org
Targeted therapies such as oral tyrosine kinase inhibitors (TKIs) are the main therapeutic
strategy effective for advanced hepatocellular carcinoma (HCC). Currently six tyrosine …
strategy effective for advanced hepatocellular carcinoma (HCC). Currently six tyrosine …
[HTML][HTML] Nanotechnology in tumor biomarker detection: The potential of liganded nanoclusters as nonlinear optical contrast agents for molecular diagnostics of cancer
Simple Summary The key factor in preventing premature death from cancer is an early and
accurate diagnosis. While common diagnostic procedures are successful in the detection …
accurate diagnosis. While common diagnostic procedures are successful in the detection …
Activation/inactivation of anticancer drugs by CYP3A4: influencing factors for personalized cancer therapy
F Wang, X Zhang, Y Wang, Y Chen, H Lu… - Drug Metabolism and …, 2023 - ASPET
Cytochrome P450 3A4 (CYP3A4), one of the most important members of the cytochrome
P450 subfamily, is a crucial catalyst in the metabolism of numerous drugs. As it catalyzes …
P450 subfamily, is a crucial catalyst in the metabolism of numerous drugs. As it catalyzes …
[HTML][HTML] Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis
K Krawczyk, K Śladowska, P Holko… - Frontiers in …, 2023 - frontiersin.org
Objective: This study aimed to compare the safety profile of tyrosine kinase inhibitors (TKIs)
approved for use as monotherapy or combination therapy for the first-line treatment of adult …
approved for use as monotherapy or combination therapy for the first-line treatment of adult …
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma
ZB Zengin, A Chehrazi-Raffle, NJ Salgia… - … Oncology: Seminars and …, 2022 - Elsevier
The management of urothelial carcinoma (UC) has rapidly advanced in recent years with
new approvals for immune checkpoint inhibitors and antibody-drug conjugates. However …
new approvals for immune checkpoint inhibitors and antibody-drug conjugates. However …
[HTML][HTML] Overview of drug-drug interactions between ritonavir-boosted Nirmatrelvir (Paxlovid) and targeted therapy and supportive care for lung cancer
K Anwar, L Nguyen, M Nagasaka, SHI Ou… - JTO Clinical and …, 2023 - Elsevier
Introduction Oral administration of ritonavir-boosted nirmatrelvir (Paxlovid) was found to be
promising in the treatment of coronavirus disease 2019. The active antiviral component …
promising in the treatment of coronavirus disease 2019. The active antiviral component …
[PDF][PDF] Lipid-based nanoformulations for TKIs delivery in cancer therapy
ZA Radmoghaddam, S Honarmand… - NanoScience …, 2022 - jnanoscitec.com
Cancer therapy faces many challenges, such as inadequate drug loading, low solubility,
leakage before reaching the target cells and killing healthy cells. Furthermore, severe side …
leakage before reaching the target cells and killing healthy cells. Furthermore, severe side …
[HTML][HTML] Ferroptosis: Frenemy of Radiotherapy
L Kerkhove, F Geirnaert, I Dufait… - International Journal of …, 2024 - mdpi.com
Recently, it was established that ferroptosis, a type of iron-dependent regulated cell death,
plays a prominent role in radiotherapy-triggered cell death. Accordingly, ferroptosis inducers …
plays a prominent role in radiotherapy-triggered cell death. Accordingly, ferroptosis inducers …
[HTML][HTML] Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer
KK Iyer, NP van Erp, DVF Tauriello… - Cancer Treatment …, 2022 - Elsevier
Patients with advanced or metastatic colorectal cancer ((m) CRC) have limited effective
treatment options resulting in high mortality rates. A better understanding of the molecular …
treatment options resulting in high mortality rates. A better understanding of the molecular …
[HTML][HTML] Exploring the impact of novel anti-cancer therapies on jaw osteonecrosis and other bones: A comprehensive review
W Konarski, T Poboży, K Konarska… - Journal of Clinical …, 2024 - mdpi.com
Osteonecrosis is a debilitating condition characterized by the loss of blood supply to the
bones, leading to bone death. This condition can impact various bones, including the jaw …
bones, leading to bone death. This condition can impact various bones, including the jaw …